SRF spin-off Revel Pharmaceuticals, a privately held biotechnology company creating therapeutics to reverse and repair damage that results from aging – particularly extracellular crosslinks – has announced recent additions to its Board of Directors and Scientific Advisory Board.
If you’ve invested in a donor-advised fund (DAF), you know that a key advantage of these funds is that they let you put charitable money aside when you have a jump in earnings, and watch for the best time and project to invest your money. We’re here (along with special guest Herbie Hancock) to tell you that now is that time!
Glucosepane crosslink breaker research graduates from top Yale lab into the biotech world Kizoo Technology Capital leads seed round financing at Revel Pharmaceuticals SAN FRANCISCO/NEW HAVEN/BERLIN, Jan. 21, 2020 — For the past 10 years, Yale Professors David Spiegel and Jason Crawford have been working on tools to enable the development of glucosepane-cleaving drugs. Kizoo …
Novel therapeutic approach to cardiovascular disease from SENS Research Foundation flagship research program graduates from laboratory to the biotech world Kizoo Technology Capital leads seed round financing at Underdog Pharmaceuticals SRF announces leadership appointments MOUNTAIN VIEW, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) — Underdog Pharmaceuticals, Inc. (Underdog), and SENS Research Foundation (SRF) today announced the …
We are seeking a full-time Research Assistant to join the Senescence Immunology group at our Research Center in Mountain View, CA, for a project geared toward developing therapies to restore the ability of the aging immune system to clear senescent cells.
UPDATE: This post has been filled. Immunologist SENS Research Foundation (SRF) is seeking a full-time researcher for a Scientist position to work at our Research Center located in Mountain View, California. The position is to lead a new intramural research project geared toward performing translational research studying aging as it relates to the immune system, …
This research program has successfully spun-out into a company! Visit the Revel Pharmaceuticals website for more information on their transformative approach to tissue cross-linking and vascular disease. Yale University Principal Investigator: David SpiegelResearch Team: Prof. Jason Crawford, Nam Kim, Venkata Sabbasani, Matthew Streeter The long-lived collagen proteins that give structure to our arteries and other …
This project has recently concluded; further information will be published in the near future. Applied StemCell, Inc. Principal Investigator: Dr. Ruby Yanru Chen-Tsai The CRISPR/Cas9 gene editing system has the ability to make precisely-targeted changes in the genetic sequence – a clear strength of the platform – but is limited in its lack of an …
This project has recently concluded; further information will be published in the near future. Buck Institute for Research on Aging Principal Investigator: Dr. Julie AndersenResearch Team: Cyrene Arputhasamy, Manish Chamoli, Anand Rane Aging brains accumulate aggregates composed of aberrant forms of the protein tau, both inside and outside of neurons. These aggregates are an important …
The Babraham Institute Principal Investigator: Jonathan ClarkResearch Team: Melanie Stammers As discussed in the project summary for “Glucosepane Crosslinks and Undoing Age-Related Tissue Damage”, adventitious crosslinking of collagen and elastin contributes to the slow stiffening of our arteries and other tissues with age. Some of these crosslinks occur as a result of spontaneous chemistry (as in …
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2024 SENS Research Foundation – ALL RIGHTS RESERVED
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2024 SENS Research Foundation – ALL RIGHTS RESERVED
